Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 12.42% | $348.55M | $971.39B | 30.21% | 72 Outperform | |
| Johnson & Johnson | 7.74% | $217.09M | $509.76B | 44.30% | 78 Outperform | |
| AbbVie | 6.05% | $169.83M | $394.69B | 28.81% | 66 Neutral | |
| UnitedHealth | 4.66% | $130.90M | $309.65B | -34.32% | 72 Outperform | |
| Merck & Company | 3.78% | $106.15M | $248.95B | -1.67% | 80 Outperform | |
| Thermo Fisher | 3.34% | $93.83M | $215.01B | 8.61% | 72 Outperform | |
| Abbott Laboratories | 3.28% | $92.10M | $218.16B | 10.65% | 73 Outperform | |
| Intuitive Surgical | 3.00% | $84.22M | $192.25B | 0.51% | 78 Outperform | |
| Amgen | 2.61% | $73.34M | $171.10B | 17.41% | 77 Outperform | |
| Gilead Sciences | 2.34% | $65.62M | $149.38B | 31.08% | 78 Outperform |